Shots:
- Engitix & GSK have entered a strategic research collaboration & option agreement to identify & validate novel therapeutic targets that drive liver fibrosis regression using Engitix’s human extracellular matrix (ECM) platform & multi-omics datasets
- As per the deal, Engitix will receive ~£44.5M (~$59.3M) upfront & near-term payments, along with ~£118M (~$157.3M) per target in downstream milestones, plus tiered low-single-digit royalties
- GSK will have the option to license generated assays, datasets, & validated targets, and will lead subsequent development & commercialization activities for selected programs
Ref: Globenewswire | Image: Engitix & GSK | Press Release
Related News: GSK Reports the P-III (B-Well 1 and B-Well 2) Trial Data on Bepirovirsen for Chronic Hepatitis B at EASL 2026
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
